Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

alzheimer

alzheimer is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 142
News articles 0
Drug details — alzheimer
Class
—
Route
—
Patents
20
Programs
142
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

alzheimer is an FDA-listed pharmaceutical active ingredient.

Key facts

INN alzheimer

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 160701 Phase 3 · Takeda · Alzheimer´s Disease
  2. 161003 Phase 3 · Takeda · Alzheimer´s Disease
  3. 161202 Phase 3 · Takeda · Alzheimer´s Disease
  4. 18F-AV-1451 Phase 3 · George Institute for · Maladie d' Alzheimer, Alzheimer's pathology
  5. 20-AVP-786-306 Phase 3 · Otsuka Beijing Research · Agitation in Patients With Dementia of the Alzheimer's Type
  6. ACP-204 Phase 3 · Acadia Pharmaceuticals · Alzheimer's Disease Psychosis
  7. ACP-204-008 Phase 3 · Anaxis Pharma · Alzheimer's Disease Psychosis
  8. AVP-786 matching placebo, AVP-786 Phase 3 · Otsuka Beijing Research · Agitation in Patients With Dementia of the Alzheimer's Type

Related patents

Browse patents

  1. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2025184490

    N-[4-FLUOR-5-[[(2S,4R)-4-[(6-MÉTHOXY-4-PYRIMIDNYL)OXY]-2-MÉTHYL-1-PYRROLIDINYL]MÉTHYL]-2-THIAZOLYL]ACÉTAMIDE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Aug 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12358892

    Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2025064824

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Mar 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11679103

    Multi-targeting agents for Alzheimer's disease therapy

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11680062

    3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11598774

    Methods of diagnosis and treatment of Alzheimer's Disease

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11571485

    Peptides and antibodies for detecting changes in alzheimer's disease brain and methods of use thereof

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11549113

    Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11541086

    Compositions and methods for treating Alzheimer's disease

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11471449

    Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11397188

    Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. CA 3201259

    MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Jun 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11278529

    Methods for treating aggression associated with Alzheimer's disease

    Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11034739

    Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10900041

    Antisense oligonucleotides for use in treating Alzheimer's disease

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10774121

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's Disease and improving normal memory

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10603311

    Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10457670

    Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is alzheimer?

alzheimer is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.